PEA, Federico
 Distribuzione geografica
Continente #
NA - Nord America 14.195
EU - Europa 3.198
AS - Asia 904
Continente sconosciuto - Info sul continente non disponibili 21
AF - Africa 16
SA - Sud America 8
Totale 18.342
Nazione #
US - Stati Uniti d'America 14.149
UA - Ucraina 1.121
IT - Italia 501
DE - Germania 500
CN - Cina 487
SE - Svezia 482
TR - Turchia 271
IE - Irlanda 214
FI - Finlandia 172
GB - Regno Unito 96
VN - Vietnam 74
CA - Canada 42
BE - Belgio 35
IN - India 35
EU - Europa 21
FR - Francia 19
RU - Federazione Russa 15
IR - Iran 12
RO - Romania 9
CH - Svizzera 8
EG - Egitto 8
HK - Hong Kong 7
KR - Corea 6
ES - Italia 5
RS - Serbia 5
BR - Brasile 4
JP - Giappone 4
NL - Olanda 4
TG - Togo 4
CZ - Repubblica Ceca 3
MX - Messico 3
TH - Thailandia 3
AR - Argentina 2
BG - Bulgaria 2
CL - Cile 2
CM - Camerun 2
PL - Polonia 2
SD - Sudan 2
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
AZ - Azerbaigian 1
BD - Bangladesh 1
HU - Ungheria 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
PA - Panama 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TW - Taiwan 1
Totale 18.342
Città #
Fairfield 2.203
Woodbridge 1.561
Chandler 1.139
Houston 1.085
Ashburn 1.048
Ann Arbor 962
Wilmington 839
Seattle 823
Cambridge 715
Jacksonville 635
Dearborn 427
Izmir 268
Beijing 262
Princeton 237
Dublin 214
Udine 194
Des Moines 143
San Diego 124
Boardman 104
Dong Ket 71
Falls Church 58
Redmond 57
New York 42
Norwalk 42
Ogden 40
Brussels 34
Grafing 33
Nanjing 30
Hefei 28
Ottawa 25
Grugliasco 22
Kunming 20
Jinan 17
San Mateo 15
Trieste 14
Bologna 13
Piemonte 12
West Jordan 12
Guangzhou 11
Milan 11
Nanchang 11
Redwood City 11
Shanghai 11
Wuhan 11
Fuzhou 9
Montreal 9
Simi Valley 9
Venezia 9
Augusta 8
Helsinki 8
Los Angeles 8
Rome 8
Monmouth Junction 7
Phoenix 7
Verona 7
Washington 7
Changsha 6
San Jose 6
Tappahannock 6
Zurich 6
Andover 5
Auburn Hills 5
Brescia 5
Hebei 5
Leawood 5
London 5
Paris 5
Shenyang 5
Wenzhou 5
Baotou 4
Edinburgh 4
Fremont 4
Hangzhou 4
Indiana 4
Lomé 4
Maserada Sul Piave 4
Napoli 4
Taizhou 4
Tokyo 4
Toronto 4
Al Qahirah al Jadidah 3
Ardabil 3
Belgrade 3
Canyon Country 3
Chengdu 3
Chiampo 3
Livorno 3
Padova 3
Résia 3
Tolmezzo 3
Torino 3
Xian 3
Zhengzhou 3
Bangkok 2
Brasília 2
Brno 2
Bucharest 2
Buffalo 2
Chicago 2
Chieti 2
Totale 13.896
Nome #
A 1 year retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: one stone for two birds? 291
A 10-Year Experience of Therapeutic Drug Monitoring (TDM) of Linezolid in a Hospital-wide Population of Patients Receiving Conventional Dosing: Is there Enough Evidence for Suggesting TDM in the Majority of Patients? 261
A regional approach to Antimicrobial Stewardship: the Friuli Venezia Giulia program 198
Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae? 190
LONG-TERM OUTCOMES OF ORTHOTOPIC LIVER TRANSPLANTATION IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS AND COMPARISON WITH HUMAN IMMUNODEFICIENCY VIRUS-NEGATIVE CASES 162
Everolimus overexposure in a heart transplant patient receiving clarithromycin for the treatment of pneumonia 161
Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with hematological malignancies 152
Educational and Organizational Interventions to Improve the Usefulness of Clinical Pharmacological Advice for Personalized Drug Dosing Based on Therapeutic Drug Monitoring. 148
Ceftolozane/tazobactam for the treatment of MDR Pseudomonas aeruginosa left ventricular assist device infection as a bridge to heart transplant 145
Stability of generic meropenem solutions for administration by continuous infusion at normal and elevated temperatures. 141
Pharmacokinetics of two oral cyclosporin a formulations in clinically stable heart-transplant patients 140
Clinical relevance of pharmacokinetics and pharmacodynamics in cardiac critical care patients 134
Risk factors associated with the onset of daptomycin non-susceptibility in Staphylococcus aureus infections in critically ill patients 132
Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations. 131
Population pharmacokinetics and pharmacodynamics of levofloxacin in acutely hospitalized older patients with various degrees of renal function 130
Cyclosporine A pharmacokinetics in rheumatoid arthritis patients after 6 months of methotrexate therapy 129
Levofloxacin PK/PD: from sequential therapy model to high dosage for critical patients 128
Valganciclovir Pharmacokinetics in Patients Receiving Oral Prophylaxis Following Kidney Transplantation and Model-Based Predictions of Optimal Dosing Regimens 128
Polypharmacy in an Italian Regional Health system: a survey on drugs use in different healthcare settings 128
Linezolid underexposure in a patient co-treated with venlafaxine 123
Antiretroviral blood levels in HIV/HCV-coinfected patients with cirrhosis after liver transplant: A report of three cases 122
What should be the first-choice strategy to maximize posaconazole exposure in daily clinical practice? 120
Clinical and pharmacokinetic drug evaluation of delafloxacin for the treatment of acute bacterial skin and skin structure infections 120
Ceftolozane/tazobactam: place in therapy 115
Treatment of consecutive episodes of multidrug-resistant bacterial pleurisy with different aetiology in a heart transplant candidate: Proof of concept of pharmacokinetic/pharmacodynamic optimisation of antimicrobial therapy at the infection site 115
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia. 114
Is empiric daptomycin effective in reducing mortality in Staphylococcus aureus bacteraemia? A real-life experience 114
Monitoring polypharmacy in healthcare systems through a multi-setting survey: Should we put more attention on long term care facilities? 114
Pharmacokinetics and drug metabolism of antibiotics in the elderly 114
Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB? 113
Is MIC increase of meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae correlated with the increase of resistance rates against some other antibiotics with Gram-negative activity? 113
Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with Candida albicans and non-albicans spp 113
Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. 112
Major role of levofloxacin in the treatment of a case of Listeria monocytogenes meningitis 111
Biliary pharmacodynamic exposure to linezolid in two liver transplant patients. 111
Continuous infusion may improve the efficacy of vancomycin in treatment of experimental endocarditis due to heterogeneous vancomycin-intermediate Staphylococcus aureus. 110
Biliary penetration and pharmacodynamic exposure of linezolid in liver transplant patients 109
Cerebrospinal fluid penetration of levofloxacin in patients with spontaneous acute bacterial meningitis 108
Cyclosporin nephrotoxicity in relation to its metabolism in psoriasis 108
Treatment of Candida Infections with Fluconazole in Adult Liver Transplant Recipients: Is TDM-guided Dosing Adaptation Helpful? 108
Linezolid disposition after standard dosages in critically ill patients undergoing continuous venovenous hemofiltration: a report of 2 cases. 107
Intra-abdominal penetration and pharmacodynamic exposure to fluconazole in three liver transplant patients with deep-seated candidiasis 107
HIV-INFECTED PATIENTS AND LIVER TRANSPLANTATION: WHO, WHEN AND WHY 106
Hyperlactacidemia Potentially Due to Linezolid Overexposure in a Liver Transplant Recipient 105
Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers. 105
Plasma pharmacokinetics of antimicrobial agents in critically Ill patients 105
Disposition of ceftobiprole during continuous venous-venous hemodiafiltration (CVVHDF) in a single critically ill patient 105
Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions 105
Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations 105
High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures 104
Liposome-encapsulated daunorubicin for PGP-related multidrug resistance 104
Linezolid underexposure in a hypothyroid patient on levothyroxine replacement therapy: A case report 104
Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia 102
Procalcitonin-guided antibiotic therapy: An expert consensus 102
Candida endocarditis and the impact of antifungal treatment on the corrected QT interval: a case report 101
Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy 101
WSES consensus conference: Guidelines for first-line management of intra-abdominal infections 101
Effect of fluctuations of blood cyclosporine concentrations on renal function. 100
- FLUCONAZOLE MONITORING IN LIVER TRANSPLANT RECIPIENTS 100
The effect of pathophysiology on pharmacokinetics in the critically ill patient - Concepts appraised by the example of antimicrobial agents 100
Pharmacokinetic/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: a step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation. 100
Antimicrobial treatment of bacterial infections in frail elderly patients: The difficult balance between efficacy, safety and tolerability 99
Antibiotic therapy in hematological neutropenic patients: what is the news? 99
Urinary Pharmacokinetics and Theoretical Pharmacodynamics of Intravenous Levofloxacin in Intensive Care Unit Patients Treated with 500 mg b.i.d. for Ventilator-Associated Pneumonia 99
Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis 98
Drugs and blood cells 98
Reappraisal of Linezolid Dosing in Renal Impairment to Improve Safety 98
Biocompatibility and biodegradation of different hyaluronan derivatives (Hyaff) implanted in rats 98
Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: A pharmacokinetics/pharmacodynamics-based approach 97
Practical concept of pharmacokinetics/pharmacodynamics in the management of skin and soft tissue infections 97
Teicoplanin therapeutic drug monitoring in critically ill patients: A retrospective study emphasizing the importance of a loading dose 96
Treatment of pyogenic (non-tuberculous) spondylodiscitis with tailored high-dose levofloxacin plus rifampicin 96
Gentamicin once-daily in enterococcal endocarditis 96
Ciprofloxacin disposition in elderly patients with LRTI being treated with sequential therapy (200 mg intravenously twice daily followed by 500 mg per os twice daily): Comparative pharmacokinetics and the role of therapeutic drug monitoring 95
Successful treatment and FDG-PET/CT monitoring of HHV-6 encephalitis in a non-neutropenic patient: case report and literature review 95
Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment? 95
Levofloxacin disposition over time in aqueous humor of patients undergoing cataract surgery 94
Effect of the number of samples on bayesian and non-linear least-squares individualization: A study of cyclosporin treatment of haematological patients with multidrug resistance 94
Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock--does the dose matter? 93
Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients 93
Higher than standard meropenem and linezolid dosages needed for appropriate treatment of an intracerebral hemorrhage patient with augmented renal clearance 92
Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia 90
Pharmacodynamics of antibiotics to treat multidrug-resistant Gram-positive hospital infections 90
Daptomycin in solid organ transplantation: Consideration of dosage adjustments in renal impairment 90
Daptomycin underexposure in a young intravenous drug user who was affected by life-threatening Staphylococcus aureus-complicated skin and soft tissue infection associated with bacteraemia 90
Could de-escalation of antibiotic therapy be feasible even for documented methicillin-resistant staphylococcus aureus ventilator-associated pneumonia? 90
Blood concentrations and clinical effect of cyclosporin in psoriasis 89
Comparison of clinical characteristics of tuberculosis between two age groups at an Italian Tertiary Hospital 89
The clinical relevance of plasma protein binding changes 89
Serum concentrations of sodium 2-mercaptoethanesulfonate (MESNA) and its metabolite, disulfide form (DIMESNA), in volunteers after oral dosing: A comparison between mesna and argimesna 89
Pharmacokinetic drug interaction between everolimus and antifungal triazoles in a liver transplant patient 89
A 5-year survey of antimicrobial susceptibility profiles of methicillin-resistant staphylococcus aureus (MRSA) isolated from patients with bloodstream infections in Northeast Italy 89
Pharmacokinetics and pharmacodynamics of continuous-infusion meropenem in pediatric hematopoietic stem cell transplant patients 89
Successful and safe long-term treatment of cerebral aspergillosis with high-dose voriconazole guided by therapeutic drug monitoring 89
Ceftobiprole: drug evaluation and place in therapy 89
Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies 88
What does it mean: Appropriate therapy for methicillin-resistant Staphylococcus aureus? [17] 88
Identification and management of invasive mycoses in internal medicine: A road-map for physicians 88
Multidrug resistance modulation in vivo. The effect of cyclosporin alone or with dextro-verapamil on idarubicin pharmacokinetics in acute leukemia 88
Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure 87
Totale 11.197
Categoria #
all - tutte 55.454
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.454


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.539 0 0 0 0 0 0 0 0 0 0 969 570
2019/20205.438 298 202 210 919 432 851 639 556 508 343 125 355
2020/20213.375 220 431 130 383 229 345 166 362 392 140 322 255
2021/20222.225 116 198 145 170 88 118 153 104 33 372 402 326
2022/20232.555 274 152 38 332 313 741 0 174 369 27 67 68
2023/2024608 126 53 20 10 114 79 20 57 71 40 18 0
Totale 19.026